FDA advisers suggest commendatory weight detriment drug

<p>TRENTON, N.J. (AP) — Advisers to supervision health regulators late Thursday endorsed that they approve sales of what would be a initial new medication weight-loss drug in a U.S. in some-more than a decade, notwithstanding concerns over cardiac risks.</p>
<p>Shares of a drug’s creator, <span>Arena Pharmaceuticals Inc.</span>, scarcely doubled, jumping from $3.66 to $7.15 in after-hours trade after trade was temporarily halted.</p>
<p>A row of consultant advisers to a <span>Food and Drug Administration</span> voted 18-4 to suggest capitulation of <span>Arena</span>‘s lorcaserin, resolved that a advantages “outweigh a intensity risks when used prolonged term” in overweight and portly people. One row member abstained from voting.</p>
<p>“We will continue to work with a FDA as a group completes a review,” Arena CEO Jack Lief pronounced in a statement.</p>
<p>The association remarkable that a FDA ha...